Numab Therapeutics raises €99.0M Series C round
20 May 2021· Horgen, Switzerland· health, biotech, immunotherapy, drug_discovery, b2b
The proceeds will support acceleration and expansion of the clinical development of Numab's lead program NM21-1480 into multiple cancer indications, and the advancement of the company's pipeline of multi-specific antibodies in oncology and inflammation, into clinical trials.
Investors
LeadNovo Holdings
Also participating
Cormorant Asset ManagementForbion (Forbion Growth Opportunities Fund)BVF Partners L.P.BlackRock-managed funds and accountsHBM PartnersRTW Investments L.P.Octagon Capital Advisors
About Numab Therapeutics
Stage
Series C
Headquarters
Horgen, Switzerland
Founded
2011
Team Size
51–200
Sectors
healthbiotechimmunotherapydrug_discoveryb2b